WeVote
Log In

Bill

Bill

S 3533

Relates to enhanced penalties for certain disaster related crimes during public emergencies

2025 Regular Session Introduced by Rob Ortt

Sets statewide, evidence-based step-therapy rules for SHBP/SEHBP/NJ FamilyCare, with fast exception decisions to protect clinician access to needed medications.

REFERRED TO VETERANS, HOMELAND SECURITY AND MILITARY AFFAIRS
0
WeVote Research Nonpartisan
Bill Summary · S 3533

Note on title: The bill text and committee reports for S-3533 address step therapy protocols for prescription drugs (health-insurance rules). The brief “Relates to enhanced penalties for certain disaster related crimes during public emergencies” appears to be an incorrect or unrelated title supplied with the request. Summary below reflects the actual bill text and committee substitute for S-3533 (step therapy).

Summary — S-3533 (Senate Committee Substitute)

Purpose

S-3533 establishes statewide standards for the design, administration, exception, appeal, and public reporting of prescription drug step therapy protocols used by the New Jersey State Health Benefits Program (SHBP), the School Employees’ Health Benefits Program (SEHBP), and NJ FamilyCare (Medicaid). The bill aims to ensure step therapy protocols are evidence‑based, transparent, and preserve clinicians’ ability to obtain immediate access to clinically necessary drugs for patients.

Key provisions

  • Definitions: Defines “step therapy protocol,” “step therapy exception,” “managed care organization,” “vendor” (third‑party administrator), and related terms.
  • Clinical criteria standards: Requires step therapy protocols to be based on clinical practice guidelines that:
    • Specifically recommend the sequence of drugs required by the protocol;
    • Are developed/endorsed by a multidisciplinary expert panel that manages conflicts of interest and relies on objective data;
    • Are based on high‑quality studies, with transparent methodology, evidence grading, consideration of patient subgroups/preferences;
    • Are reviewed at least annually (or quarterly if new clinical information appears) and updated when warranted.
    • In absence of such guidelines, peer‑reviewed literature may be used.
  • Access to clinical criteria: Managed care organizations (MCOs) and vendors must provide written clinical review criteria on request and make them available on their websites.
  • Step therapy exception process:
    • Plans/MCOs must offer a clear, readily accessible process (existing medical‑exception processes may be reused) for clinicians and enrollees to request exceptions.
    • Exceptions must be granted when the prescriber determines that: the required drug is contraindicated or harmful; is expected to be ineffective for the patient; or alternative/formulary drugs have been ineffective or caused adverse reactions.
    • Prescribers must provide documentation if requested.
    • When granted, coverage must be authorized for at least 180 days (or the duration of therapy if less), provided the drug is covered by the plan.
  • Decision timeframes: The bill requires decisions to be made consistent with the medical urgency of the case and specifies maximum windows — generally 24 hours for urgent requests and 72 hours for non‑urgent requests after receipt of all necessary information. Committee language also provides that an untimely response may be deemed a grant in certain versions.
  • Appeals and public reporting: Exceptions and denials are subject to appeal. Carriers, utilization review organizations, and MCOs must report specified data (numbers/nature of exception requests, appeals, approvals, denials) to the Commissioner of Banking and Insurance; some reporting must be publicly available.
  • Medicaid implementation: The Department of Human Services must seek any necessary State Plan Amendments or waivers to implement provisions for NJ FamilyCare and to secure federal matching funds.

Who is affected

  • Directly: SHBP, SEHBP, NJ FamilyCare (Medicaid) beneficiaries, their prescribing clinicians, managed care organizations under Medicaid, vendors/third‑party administrators that administer plan functions, and utilization review entities contracting with these plans.
  • Indirectly: State and local budgets (for plans participating in SHBP/SEHBP), and the Department of Human Services and Commissioner of Banking and Insurance (administrative responsibilities).
  • Exemptions: Commercial market plans were excluded in some versions; the final committee substitute specifically covers the State plans named above.

Procedural status & sponsors

  • Introduced: Sept 12, 2024.
  • Committee actions: Reported favorably by Senate Commerce Committee (Oct 10, 2024); substitute reported by Senate Budget & Appropriations Committee (Mar 17, 2025); substituted by A-1825 (Mar 24, 2025).
  • Referred to Veterans, Homeland Security and Military Affairs (Jan 28, 2025) per bill actions log.
  • Primary sponsors: Senator Angela V. McKnight and Senator Robert Ortt.
  • Companion: A-1825.

Fiscal and operational impact

  • Office of Legislative Services (OLS) estimates the bill will increase annual State (and in some analyses, local) prescription drug expenditures by an indeterminate amount because step‑therapy overrides may result in more use of higher‑cost drugs. There is potential for offsetting savings if improved clinical outcomes reduce downstream costs.
  • Higher Medicaid (NJ FamilyCare) spending may increase federal matching funds (OLS notes an average federal match of ~$0.64 per $1.00 of qualifying State spending).
  • Agencies (Department of Human Services; Division of Pensions & Benefits; Department of Banking and Insurance) may incur administrative costs related to guideline oversight, reporting, and implementing any required federal plan amendments/waivers.

Key implementation timelines/process notes

  • Clinical guidelines must be periodically reviewed (annual or quarterly as specified).
  • Exception decisions must be rendered rapidly (24/72 hour windows) to accommodate exigent medical needs.
  • Department of Human Services must apply for necessary federal approvals for Medicaid implementation.

Limitations / variants to note

  • Earlier and introduced versions differ in scope language; the committee substitute focuses on SHBP, SEHBP, and Medicaid.
  • Some committee documents indicate deemed‑granted rules for untimely responses; consult final enrolled language for exact default provisions.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.